Showing 1 - 10 of 1,417
protection. We use new survey data from India, the results of interviews with industry, government and multinational institutions …
Persistent link: https://www.econbiz.de/10012471281
pharmaceutical trade data from 1996 to 2005, we examine the role of China and India as suppliers of medicines to other middle- and … medicines from high- income countries. We find that imports of antibiotics and unspecified medicaments from India and China … significantly depress the average price of these commodities imported from high-income trading partners, suggesting that India and …
Persistent link: https://www.econbiz.de/10012461408
relative magnitudes of the two sources of competition in limiting innovative returns in the U.S. pharmaceuticals market. In …
Persistent link: https://www.econbiz.de/10012469403
pharmaceuticals that were compliant with the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS). We combine …In 2005, as the result of a World Trade Organization mandate, India began to implement product patents for … pharmaceutical product sales data for India with a newly gathered dataset of molecule-linked patents issued by the Indian patent …
Persistent link: https://www.econbiz.de/10012458117
By thoroughly controlling for the country covariates, through a combination of matched sampling techniques with fixed-effect panel regression models, the analyses arrive at robust results across the various model specifications. First, national pharmaceutical patent protection alone does not...
Persistent link: https://www.econbiz.de/10012462357
There is a long-standing literature that recognizes that an efficient solution in correcting a consumption externality is through applying subsidies and taxes that line up private incentives with social ones. An equally long-standing literature tackles the appropriate methods of generating the...
Persistent link: https://www.econbiz.de/10012469100
We study the determinants of patent suits and their outcomes over the period 1978-1999 by linking detailed information from the U.S. patent office, the federal court system, and industry sources. The probability of being involved in a suit is very heterogeneous, being much higher for valuable...
Persistent link: https://www.econbiz.de/10012470059
discusses the various theoretical implications for a developing country of introducing product patents for pharmaceuticals …. Using India as an example, it then brings together information gathered from both published sources and personal interviews …
Persistent link: https://www.econbiz.de/10012472451
countries with restrictions on secondary patents, India, Brazil, and Argentina. We examine cross-country comparisons of primary …
Persistent link: https://www.econbiz.de/10012455567
tuberculosis drug samples that claim to be made in India and were sold in Africa, India, and five mid-income non-African countries … in India or non-African countries. Since this finding is robust for manufacturer-drug fixed effects, one likely …
Persistent link: https://www.econbiz.de/10012458199